Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059)
- PMID: 34053734
- DOI: 10.1016/j.ophtha.2021.04.029
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059)
Comment in
-
Reply.Ophthalmology. 2021 Sep;128(9):e47-e48. doi: 10.1016/j.ophtha.2021.04.030. Epub 2021 May 27. Ophthalmology. 2021. PMID: 34053735 No abstract available.
Comment on
-
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15. Ophthalmology. 2021. PMID: 33207259 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
